Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy-Reference-Cited by-同舟云学术

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy

Published:2021-12 Issue: Volume:26 Page:174-191
ISSN:2162-2531
Container-title:Molecular Therapy - Nucleic Acids
language:en
Short-container-title:Molecular Therapy - Nucleic Acids

Author:

Cerro-Herreros Estefanía,González-Martínez Irene,Moreno Nerea,Espinosa-Espinosa Jorge^ORCID,Fernández-Costa Juan M.,Colom-Rodrigo Anna,Overby Sarah J.^ORCID,Seoane-Miraz David,Poyatos-García Javier^ORCID,Vilchez Juan J.,López de Munain Adolfo,Varela Miguel A.^ORCID,Wood Matthew J.,Pérez-Alonso Manuel,Llamusí Beatriz,Artero Rubén

Funder

Carlos III Health Institute

Publisher

Elsevier BV

Subject

Drug Discovery,Molecular Medicine

Reference74 articles.

1. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy;Miller;EMBO J.,2000

2. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts;Fardaei;Nucleic Acids Res.,2001

3. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1;Lee;Proc. Natl. Acad. Sci. USA,2012

4. Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1;Pandey;J. Pharmacol. Exp. Ther.,2015

5. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I;Zhang;Hum. Mol. Genet.,2017

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression;Molecular Therapy - Nucleic Acids;2023-12

2. miR-218 Promotes Dopaminergic Differentiation and Controls Neuron Excitability and Neurotransmitter Release through the Regulation of a Synaptic-Related Genes Network;The Journal of Neuroscience;2023-10-10

3. BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSALR Mice;Pharmaceutics;2023-03-31

4. The myotonic dystrophy type 1 drug development pipeline: 2022 edition;Drug Discovery Today;2023-03

5. Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1;International Journal of Molecular Sciences;2023-01-31